

M6AREG: m⁶A-centered regulation of disease development and drug response

Shuiping Liu^{1,2,*}, Lu Chen^{1,†}, Yintao Zhang^{3,4,†}, Ying Zhou^{5,†}, Ying He¹, Zhen Chen^{3,4}, Shasha Qi¹, Jinyu Zhu¹, Xudong Chen¹, Hao Zhang¹, Yongchao Luo^{3,4}, Yunqing Qiu⁵, Lin Tao^{1,*} and Feng Zhu^{1,3,4,*}

¹Key Laboratory of Elemene Class Anti-Cancer Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Zhejiang Province, School of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China, ²Laboratory of Cancer Genomics, Division of Cellular and Molecular Research, National Cancer Centre Singapore, Singapore 169610, Singapore, ³College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, Zhejiang University, Hangzhou 310058, China, ⁴Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare, Hangzhou 330110, China and ⁵State Key Laboratory for Diagnosis and Treatment of Infectious Disease, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Zhejiang Provincial Key Laboratory for Drug Clinical Research and Evaluation, The First Affiliated Hospital, Zhejiang University, Hangzhou, 310000, China


Received August 09, 2022; Revised August 27, 2022; Editorial Decision September 02, 2022; Accepted September 06, 2022

ABSTRACT

As the most prevalent internal modification in eukaryotic RNAs, N⁶-methyladenosine (m⁶A) has been discovered to play an essential role in cellular proliferation, metabolic homeostasis, embryonic development, etc. With the rapid accumulation of research interest in m⁶A, its crucial roles in the regulations of disease development and drug response are gaining more and more attention. Thus, a database offering such valuable data on m⁶A-centered regulation is greatly needed; however, no such database is as yet available. Herein, a new database named 'M6AREG' is developed to (i) systematically cover, for the first time, data on the effects of m⁶A-centered regulation on both disease development and drug response, (ii) explicitly describe the molecular mechanism underlying each type of regulation and (iii) fully reference the collected data by cross-linking to existing databases. Since the accumulated data are valuable for researchers in diverse disciplines (such as pathology and pathophysiology, clinical laboratory diagnostics, medicinal biochemistry and drug design), M6AREG is expected to have many implications for the future conduct of m⁶A-based regula-

tion studies. It is currently accessible by all users at: <https://idrblab.org/m6areg/>

GRAPHICAL ABSTRACT



INTRODUCTION

As the most prevalent internal modification in eukaryotic RNAs, N⁶-methyladenosine (m⁶A) is widely known to play essential roles in cellular proliferation, metabolic homeostasis, embryonic development, and so on (1–6). With the rapid

*To whom correspondence should be addressed. Tel: +86 189 8946 6518; Fax: +86 571 8820 8444; Email: zhufeng@zju.edu.cn

Correspondence may also be addressed to Lin Tao. Email: taolin@hznu.edu.cn

Correspondence may also be addressed to Shuiping Liu. Email: lsp@hznu.edu.cn

†The authors wish it to be known that, in their opinion, the first four authors should be regarded as Joint First Authors.

increase in research interest in m⁶A, its crucial roles in the occurrence and progression of various diseases, including cardiovascular disease (7), influenza (8), gastroenteritis (9), liver fibrosis (10), diabetes (11) and cancer (12), are gaining more and more attention. Moreover, various types of m⁶A regulation are found to affect the responses of a drug in its corresponding disease via mediating the expression of target genes (13–15). In other words, the regulation of disease development and drug response by m⁶A has emerged as one of the most promising directions in recent years (7–19), and various studies have been conducted to uncover the molecular mechanism underlying regulation (mediated by the regulators of methyltransferase (writers), demethylase (erasers) and m⁶A-binding proteins (readers) (20–22).

The above-mentioned studies have accumulated valuable data for researchers in the diverse directions of (i) pathology and pathophysiology clarifying the essential role of m⁶A modifications in the occurrence/progression of disease (23–26), (ii) clinical laboratory diagnostics promoting the discovery of new therapeutic targets (27–31) and diagnostic/prognostic biomarkers (32–37) and (iii) medicinal biochemistry and drug design facilitating the discovery of m⁶A's mechanisms in determining drug sensitivity and the design of new drug and drug combinations (38–42). Therefore, it is essential to have a database that provides data on the effect of m⁶A-centered regulation on disease development and drug response, together with the molecular mechanisms underlying each type of regulation.

So far, a variety of popular m⁶A-related databases have been developed (43–52). Some focus on describing the genome-wide landscape of RNA modification, variants and a variant's effect on post-transcriptional regulation [such as RMDisease (43), RMBase (44) and RMVar (45)]. Some others aim to show the m⁶A modification sites of RNAs based on sequencing experiments and transcriptome-wide prediction [such as m⁶A-Atlas (46), WHISTLE (47), m⁶Avar (48) and SRAMP (49)]. The remaining databases provide the validated or predicted targets of m⁶A regulators based on low-/high-throughput studies [such as MeT-DB (50) and M6A2Target (51)]. The majority of these existing databases have been frequently accessed and highly cited due to their considerable contributions to the needs of research communities (44–50). However, to date, there is no database available to provide data of m⁶A-centered regulation of disease development and drug response. Moreover, such a database is needed to systematically describe the molecular mechanisms underlying each type of regulation.

Herein, a database named 'm⁶A-centered regulations of disease development and drug response (M6AREG)' is therefore introduced. First, a systematic literature review on m⁶A's regulation of disease development and drug response was conducted. The development of various diseases and the response data of drugs that were reported to be regulated by the corresponding m⁶A were systematically collected into the M6AREG database. Second, the molecular mechanisms underlying each type of regulation discussed above were then retrieved from the literature. The target RNAs regulated by the identified m⁶A regulators and their corresponding pathways were systematically collected. In

particular, their regulation profiles (including m⁶A modification pattern, up-/down-regulation of expression and the cell processes regulated) were provided. Finally, because some xenobiotics were reported to interact with and mediate a particular m⁶A regulator (53–55), a number of xenobiotics regulating disease development and drug response through the mediation of certain m⁶A regulators were also provided. M6AREG data were also fully cross-linked to available databases. Since the data provided in M6AREG (<https://idrblab.org/m6areg/>) are valuable for diverse directions, it is expected to have great implications for the future conduct of m⁶A-based regulation studies.

FACTUAL CONTENT AND DATA RETRIEVAL

Data collection for m⁶A-centered regulation

Data on m⁶A-centered regulation of disease developments and drug responses were collected based on the following procedure. First, a large number of diseases, drugs and the m⁶A regulators were retrieved from ICD-11 (56), DrugBank (57), TTD (58), NCBI Gene (59), UniProt (60) and HGNC (61). Second, the data about m⁶A-centered regulations of disease development and drug response were collected by a comprehensive literature review in PubMed (59) using the keywords: 'm⁶A + disease', 'm⁶A + drug', 'm⁶A Regulator Name + disease', 'm⁶A Regulator Name + drug', 'm⁶A + Disease Name', 'm⁶A + Drug Name', 'Regulator Name + Disease Name', 'Regulator Name + Drug Name', etc. As a result, the development of 165 classes of diseases (such as diabetes, lung cancer and rheumatoid arthritis) and the response data of 70 drugs (such as cisplatin, sorafenib and tamoxifen) which were regulated by 31 regulators (such as FTO, METTL3 and ALKBH5) were collected in M6AREG. Third, all identified publications were reviewed and their detailed regulation information was manually collected, which included cell lines, animal models, targets and pathways. In addition, a total of 93 xenobiotics that regulated disease development and drug response via affecting m⁶A regulators were also collected.

The m⁶A regulators and their biological function

The m⁶A modification is an important RNA methylation without affecting the nucleotide sequence, which is achieved by m⁶A regulators (14). Such regulators include writers (e.g. METTL3, METTL14 and METTL16), erasers (e.g. FTO and ALKBH5) and readers (e.g. YTHDC1-2, IGF2BP1-3 and SND1), which have been reported to play key biological roles in many epigenetic directions, such as the mRNA life cycle and the cellular/developmental/disease process (62).

The biological function of writers, erasers and readers. As shown in Figure 1, m⁶A methyltransferase complexes are composed of the catalytic core METTL3, the RNA support element METTL14, the stabilizer WTAP and various adaptors [e.g. RBM1515B, ZC3H13, GBL1 and VIRMA (63,64)]. m⁶A modifications are reversible and dynamic, since they can be removed by erasers, such as FTO and ALKBH5. Both writers and erasers regulating the level of




Figure 1. Function and corresponding mechanism of m⁶A writers and erasers in various cellular processes. The m⁶A modification is reversible and dynamic, which can not only be introduced into various target RNAs using the core methyltransferase complex (METTL3/METTL14/WTAP) and other adaptors, but can also be removed by the demethylases. These m⁶A-regulated RNAs which are involved in disease occurrence/progression and drug response were collected in M6AREG.

a target's m⁶A modification by methylation or demethylation play a critical role in the development of different classes of diseases (such as cancer, diabetes and rheumatoid arthritis) and drug response by targeting both coding and non-coding RNA (65–68). Taking the oscillatory shear stress-induced proatherogenic process as an example (shown in Figure 2), the expression of a writer METTL3 is up-regulated, which induces METTL3-dependent m⁶A hypermethylation of two targets (NLRP1 and KLF4), and then results in the elicitation of atherogenic responses, such as inflammation and cell adhesion (69). Another example of a writer is METTL14, which is reported to be remarkably down-regulated in trastuzumab-resistant cancer cells compared with their parental HER2-positive breast cancer cells. Some mechanistic studies reveal that it decreases the expression of FGFR4 by m⁶A modification (as shown in Figure 2), and FGFR4 could phosphorylate GSK-3 β and stimulate β -catenin/TCF4 signaling to drive anti-HER2 resistance (70,71). Moreover, the first identified m⁶A demethylase (eraser), FTO, is found to play critical roles in leukemogenesis and drug response. It promotes leukemic oncogene-mediated cell transformation and leukemogenesis, and inhibits all-*trans*-retinoic acid-induced leukemia cell differentiation. Mechanistic studies show that FTO performs its oncogenic role by reducing the m⁶A level in mRNA tran-

scripts of ASB2 and RARA, and then decreasing their expression (72).

Once RNA has been m⁶A methylated, the m⁶A writers (including YTHDFs, YTHDCs, IGF2BPs, eIF3, HNRNPs and FMRPs) could bind to the methylation site and play a specific role in RNA nuclear export, stabilization, splicing, translation and decay (73,74). As shown in Figure 3, due to such characteristics, great diversity in the m⁶A modification pattern and expression regulation (up-/down-) toward target RNAs was exhibited, which resulted in different regulation mechanisms in diseases and drug responses (75,76). As illustrated in Figure 2, the m⁶A reader HNRNPA2B1 is up-regulated in multiple myeloma and negatively correlated with a favorable prognosis. It promotes multiple myeloma progression (such as promoting cell proliferation and inhibiting cell apoptosis) by stabilizing the mRNA of ILF3 and AKT3 (77). Another example of a reader is YTHDF2, which causes the decay of PD-1, CXCR4 and SOX10, and then sensitizes melanoma cells to interferon γ and anti-PD-1 (76). As a subtype of YTHDF, YTHDF1 mediates m⁶A-increased translation of Snail that is a key transcription factor of the epithelial–mesenchymal transition, which has been considered as a negative prognostic factor for the overall survival rate of liver cancer patients (78).




Figure 2. Representative examples describing the roles and corresponding molecular mechanisms of each m^6A regulator in disease development and drug response. The m^6A writer METTL3 can induce hypermethylation of NLRP1 and KLF4, and then up-regulate NLRP1 while downregulating KLF4 to elicit an atherogenic responses such as inflammation and cell adhesion. METTL14 decreases FGFR4 expression which could phosphorylate GSK-3 β and stimulate β -catenin/TCF4 signaling to drive anti-HER2 resistance. FTO, as an eraser, promotes leukemogenesis and inhibits all-*trans*-retinoic acid-induced leukemia cell differentiation via reducing the m^6A level in mRNA transcripts of *ASB2* and *RAR*. The m^6A readers, HNRNPA2B1, YTHDF1 and YTHDF2 individually promote multiple myeloma progression via stabilizing ILF3 mRNA, upregulating key transcription factors of the epithelial–mesenchymal transition in cancer via increasing translation of Snail, and sensitize melanoma cells to interferon γ and anti-PD-1 by causing the decay of PD-1, CXCR4 and SOX10.

The description and statistics of regulators in M6AREG. For each m^6A regulator shown in M6AREG, the detailed descriptions on its general information were provided online, which included regulator name, synonyms, gene name, sequence, protein family, biological function, regulator type, a full list of potential target genes of the regulator and other molecular information associated with the external links to NCBI Gene (59), UniProt (60), etc. The potential targets for a certain m^6A regulator were discovered based on the transcriptomic studies collected from GEO (79), such as RIP seq, CLIP-seq, eCLIP-seq, PARCLIP-seq, iCLIP-seq and RNA-seq. For each regulator and its targets, detailed information such as gene name, experimental method, fold change, cell line and the external links to GEO (79), NCBI Gene (59), UniProt (60), etc. was also described. A diagram of the mechanism of each m^6A regulator was also provided in the regulator page of the M6AREG

database, which included representative information of its role in m^6A modification, interactions with other regulators, target genes, etc. A full list of experimentally validated disease development and drug responses that were mediated by this regulator was provided, and detailed information, such as the m^6A regulation pattern, *in vivo/in vitro* model and pathway, was also provided.

All in all, 14 m^6A writers were reported to be involved in the development of 57 diseases by targeting 317 RNAs in 469 cell lines, and two m^6A erasers were found to participate in the development of 49 diseases by targeting 164 RNAs in 335 cell line models. The studies on mechanisms showed that m^6A writers and erasers regulated different cellular processes (such as the cell cycle and immunity) by regulating 89 and 64 signaling pathways (such as apoptosis, mTOR signaling and nucleotide excision repair), respectively. These regulators greatly affected the efficacies of a




Figure 3. Different roles and mechanisms of m⁶A readers in various cell processes. Once the RNAs have been modified, different m⁶A writers will bind to the modification sites and perform diverse functions (RNA nuclear export, stabilization, translation, splicing and decay), which results in the up-/down-regulation of target genes. All RNAs that are involved in the regulation of disease occurrence/development and drug response of m⁶A writers were collected and explicitly described in M6AREG.

variety of drugs (such as cisplatin and sorafenib). Moreover, 15 m⁶A readers were identified to participate in the development of 41 diseases by targeting 217 RNAs in 391 cell lines, which were actively involved in 73 signaling pathways and significantly affected the responses of a variety of drugs.

For an m⁶A-based database, it is key to provide a quantitative description on the up-/down-regulation of the m⁶A target genes. The RNA-seq data were therefore incorporated into this newly developed database. First, a systematic review was conducted in GEO (79) to retrieve the regulator-related RNA-seq data by searching keywords such as ‘m⁶A Regulator Name’, ‘m⁶A Regulator Name + RNA sequencing’, ‘m⁶A Regulator Name + RNA seq’, and so on. The comparative data that studied the gene expression variations by knocking out, knocking down or overexpressing certain regulators were collected, which led to a total of 236 GEO datasets. Second, these newly collected datasets were carefully reviewed, and those datasets without a clearly stated data pre-processing method or of <2 samples for the control/case group were excluded from our analysis (80,81). As a result, a total of 144 datasets were identified for subsequent differential expression analyses. Third, the ‘raw read

count’ and ‘TPM’ datasets were analyzed using the DESeq2 and limma packages, respectively (82–84), and the ‘RPKM’ and ‘FPKM’ datasets were transformed to ‘TPM’ and then analyzed using the limma package (85). The genes identified as significantly differentially expressed (fold change >1.5 and *P*-value <0.05) were considered as regulated by the studied regulator (86,87). Finally, the differential expression patterns of 33 889 target genes that were regulated by at least one regulator were collected, and the quantitative description of such a regulated expression pattern was provided in the regulator page and target page of the M6AREG database (as illustrated in Figure 4). Detailed information such as experimental conditions, cell line and species was also described.

The m⁶A-centered regulation of disease development

Dynamic m⁶A modification is reported to be involved in multiple biological processes by affecting gene expression of multiple levels including tissue development, self-renewal and differentiation of stem cells, circadian rhythm, heat shock, metabolism, metastasis and sex determination (15). With the advances in technology, increasing evidence




Figure 4. Quantitative description of the regulation pattern of target genes by m⁶A regulators. For a target gene and corresponding m⁶A regulator, the differential gene expression of the target gene in cells with treatment (knockout, knockdown and overexpression) and control cells was provided in the form of a bar chart and boxplot together with fold change and *P*-values, which were based on the RNA-seq data collected from the GEO. Detailed information such as cell line, species and experimental condition was also explicitly described. Pink, target gene expression of the cells with treatment; blue, target gene expression of the control cells.

showed that m⁶A modification plays crucial roles in the occurrence/progression of various disease (7–12). Recent literature indicated that m⁶A modification could be a new molecular tool to understand the occurrence and progression of diseases, which is regulated by many m⁶A regulators (24,88,89), and an increasing number of m⁶A regulators and their corresponding target gene were identified to have clinical implications in either diagnosis/prognosis or therapy for various diseases (24,90,91).

To obtain such m⁶A-centered regulation data, the disease-specific regulation data of both molecules and pathways were systematically reviewed and explicitly described in M6AREG. A total of 165 diseases were identified to be regulated by m⁶A modification according to the latest International Classification of Diseases (56). In particular, a total of 747 RNA molecules (e.g. mRNA, lncRNA, miRNA and cirRNA) and 78 pathways (physiological/pathological) that were regulated by 30 regulators (e.g. METTL3, FTO and YTHDF2) were collected. First, general information on each disease related to an m⁶A regulator and target genes (such as autophagy-related protein, cyclin-dependent kinase, microRNA and lncRNA) were provided. Second, as illustrated in Figure 5, the involved cellular processes of each target gene were described, which included cell

growth, cell cycle, cell migration, cell proliferation and macrophage infiltration. Third, the regulation mechanisms of target genes in m⁶A-centered disease responses were also collected, which included the m⁶A regulators involved, up-/down-regulation of target genes and regulated pathways (e.g. PI3K–Akt signaling, TNF signaling and JAK–STAT signaling). Such data on m⁶A-centered regulation were essential for understanding of the mechanism underlying target genes in m⁶A-centered disease response. Fourth, besides the involved cellular processes and regulation mechanism data, *in vitro* and *in vivo* disease models were also illustrated in M6AREG. As described in Figure 5, a total of 200 cell lines of various diseases together with 23 model organisms were collected and provided in this newly developed database. Fifth, the comprehensive information for each target gene can be accessed by clicking the ‘Target Info’ button, which includes target name, synonyms, gene name, chromosomal location, functions and links to existing databases (59–61). Meanwhile, the comprehensive data of m⁶A regulators can be accessed by clicking the ‘Regulator Info’ buttons, and both the pathways altered by the m⁶A regulators and the corresponding *in vitro* models were directly linked to the KEGG (92) and Cellosaurus (93) databases.

General Information of the Disease (ID: M6ADIS0059) ▼

Name	Colorectal cancer
ICD	ICD-11: 2B91

Full List of Target Gene(s) of This m6A-centered Disease Response ▼

- ▶ **AMPK subunit alpha-2 (AMPKAlpha2/PRKAA2)** Target Info
- ▶ **Catenin beta-1 (CTNNB1/Beta-catenin)** Target Info
- ▼ **Class E basic helix-loop-helix protein 41 (BHLHE41)** Target Info

In total 1 item(s) under this target gene

Experiment 1 Reporting the m6A-centered Disease Response by This Target Gene [6]

Response Summary	METTL3 promoted <i>Class E basic helix-loop-helix protein 41 (BHLHE41)</i> expression in m6A-dependent manner, which subsequently induced CXCL1 transcription to enhance MDSC migration in vitro. METTL3 as a potential therapeutic target for CRC immunotherapy whose inhibition reverses immune suppression through m6A-BHLHE41-CXCL1 axis.		
Responded Disease	Colorectal cancer [ICD-11: 2B91]		
Target Regulator	Methyltransferase-like 3 (METTL3)	WRITER	Regulator Info
Target Regulation	Up regulation		
Pathway Response	Cytokine-cytokine receptor interaction	hsa04060 ↗	
	Chemokine signaling pathway	hsa04062 ↗	
Cell Process	Cell immunity		
	Cell growth		
	Cell migration		
In-vitro Model	CT26	Mouse colon adenocarcinoma	Mus musculus CVCL_7254 ↗
	MC-38	Mouse colon adenocarcinoma	Mus musculus CVCL_B288 ↗
	HEK293T	Normal	Homo sapiens CVCL_0063 ↗
In-vivo Model	METTL3 knockout or control CT26 and MC38 cells were injected subcutaneously into the dorsal flank of each 4- to 6-week-old male immunocompetent BALB/c and C57BL/6 mice, respectively. Anti-Gr-1 (BE0075; Bio-X-Cell, Lebanon, NH) or immunoglobulin (Ig)G isotype control (BE0090, Bio-X-Cell) was given every other day via intraperitoneal injection (150 ug/mouse). SB-265610 (Tocris, Bristol, UK) or phosphate-buffered saline was administered through intraperitoneal injections at a dosage of 2 mg/kg per day. Tumor sizes were measured every other day. To establish an orthotopic mouse model of CRC, 5- to 6-week-old male C57BL/6 mice were treated with 1.7% dextran sodium sulfate in drinking water for 5 days, and then allowed to recover for 3 days. After 24 hours of fasting, METTL3 knockout or control MC38 cells suspended in 50 ul of 1 mg/mL Matrigel-phosphate-buffered saline (Corning, Corning, NY) were instilled into the colon lumen of anesthetized mice, coated sparingly with Vaseline.		

- ▶ **Cyclic AMP-dependent transcription factor ATF-4 (ATF4)** Target Info
- ▶ **E3 ubiquitin-protein ligase SIAH1 (SIAH1)** Target Info

Figure 5. Regulation of target genes and pathways by m⁶A regulators in disease occurrence and progression. The detailed mechanism underlying m⁶A-centered disease responses is shown, which included a summary of disease responses, the m⁶A regulators involved, up-/down-regulation of target genes, regulated pathways, cellular processes and *in vitro/in vivo* disease models used. Extended descriptions can be accessed by clicking the corresponding differently colored buttons.

The m⁶A-centered regulation of drug responses


In the course of drug therapy, the clinical treatment effect on a patient can be seriously affected by the lack of alternative drugs and mutations in drug response-related genes (94). An increasing number of studies showed that the m⁶A modification plays a vital role in drug response of various diseases, which could be regulated by various m⁶A regulators and multiple target genes modulated by the same regulator (15,73,95). The m⁶A regulators altered drug responses by modulating drug–target interaction and drug-mediated cell death signaling. On the one hand, m⁶A modification interfered with drug efficacy that was mediated by a multidrug efflux transporter, drug-metabolizing enzyme and drug target (96–98). On the other hand, alterations of the m⁶A modification can inhibit drug-mediated cell death by inducing DNA damage and modulating its repair capac-

ity (73). A number of studies indicated that m⁶A regulators or their corresponding target genes have potential as drug–effect biomarkers in disease (99,100), and diverse xenobiotics could bind to m⁶A regulators and modify their activities, resulting in regulation of disease progression or drug response (53,54).


As shown in Figure 6, a total of 70 drugs were identified to be regulated by 21 regulators, which were verified by *in vitro/in vivo* experiments. General information on each drug [such as drug name, synonym, clinic status, structure, formula, International Chemical Identifier (InChI) and InChIKey] is provided, and a list of m⁶A target genes associated with this drug response are described in M6AREG. For each m⁶A target gene, the summary of the target-regulated drug response, response disease, involved regulator, target regulation, pathway response, cellular process and *in vitro/in vivo* models are also described

General Information of the Drug (ID: M6ADRUG0032)

Name	Sorafenib		
Synonyms	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-[4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl]urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-[4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl]urea; Click to Show/Hide		
Status	Approved	[1]	



3D MOL



2D MOL

Full List of m6A Targets Related to This Drug

- ▶ **Beclin-1 (BECN1)** Target Info
- ▶ **Hepatocyte nuclear factor 3-gamma (HNF3gamma/FOXA3)** Target Info

In total 1 item(s) under this target gene

[Experiment 1 Reporting the m6A-centered Drug Response by This Target Gene](#) [5]

Response Summary	The <i>Hepatocyte nuclear factor 3-gamma (HNF3gamma/FOXA3)</i> reduction in <i>hepatocellular carcinoma</i> could be mediated by <i>METTL14</i> -dependent m6A methylation of HNF3-Gamma mRNA. HNF3-Gamma plays an essential role in HCC differentiation and serves as a therapeutic target and predictor of <i>sorafenib</i> benefit in patients.		
Responded Disease	Hepatocellular carcinoma	ICD-11: 2C12.02	Disease Info
Target Regulator	Methyltransferase-like 14 (METTL14)	WRITER	Regulator Info
Target Regulation	Down regulation		
Cell Process	Membrane transport Cell apoptosis		
In-vitro Model	HCCLM3	Adult hepatocellular carcinoma	Homo sapiens CVCL_6832 ↗
	Huh-7	Adult hepatocellular carcinoma	Homo sapiens CVCL_0336 ↗
In-vivo Model	When xenografted tumor growth reached 500 mm ³ , the mice were subjected to intratumoral injection of Ad-con or Ad-HNF3γ every other day. For the PDX model, fresh patient HCC tissues were cut into fragments with a volume of 3 × 3 mm ³ and then implanted subcutaneously into the flanks of nude mice. The mice were given sorafenib (30 mg/kg) or vehicle orally twice a week for 24 days.		

- ▶ **Translocating chain-associated membrane protein 2 (TRAM2)** Target Info
- ▶ **Long intergenic non-protein coding RNA 1273 (LINC01273)** Target Info

Figure 6. A typical page describing the m⁶A-centered regulations of drug responses. General information on the drug and its m⁶A targets are shown. For each target, the experimentally validated mechanisms are explicitly described. The regulation data are linked to their cell line or animal models, and extended information (such as each involved disease, target gene and regulated pathway) can also be retrieved by clicking the corresponding differently colored buttons.

(illustrated in Figure 6). Moreover, the additional description of each target, m⁶A regulator and disease relevant to this drug can be accessed through clicking 'Target Info', 'Regulator Info' and 'Disease Info', respectively. All in all, a total of 146 experimentally verified targets, 36 pathways (physiological/pathological), 46 cellular processes, 269 cell lines and 75 *in vivo* animal models were found to be involved in identifying drug response alterations which were mediated by m⁶A modification, which are all provided in M6AREG. Based on those data provided on M6AREG's drug page, the user can readily retrieve a list of m⁶A tar-

gets that were involved in the therapeutic effects of the corresponding drug described.

Moreover, it is well known that some of the leading causes of drug efficiency include the mutation/altered expression of target proteins, deregulated drug transporters and altered drug metabolism, and the m⁶A regulators are reported to play a vital role in affecting the drug response by acting on the related molecules (73,101–105). Thus, the potential drug responses mediated by a specific m⁶A regulator are collected into M6AREG. First, three types of critical proteins (drug targets, transporters and metabolic enzymes) were identi-

fied from experimentally verified targets of m⁶A regulators. Second, the drugs targeting these three types of critical proteins were collected. As a result, a total of 4258 drugs including 593 approved drugs were found to interact with these types of targets that were regulated by m⁶A modification. All drugs can be accessed at the bottom of the regulator page, which provides the drug name, drug clinical status and mechanism leading to the drug response. Detailed information can be retrieved by clicking the button ‘Drug Info’.

M6AREG data standardization, access and retrieval

To facilitate users accessing and analyzing the M6AREG data, the collected raw data were carefully cleaned up and then systematically standardized. The standardizations included (i) all M6AREG diseases were standardized based on the latest version of the International Classification of Disease (56); (ii) all genes, RNAs, proteins, pathways and *in vitro* models in M6AREG were standardized and cross-linked to popular databases (such as NCBI Gene, HGNC, miRbase, Ensembl, UniProt, KEGG and Cellosaurus); and (iii) M6AREG drugs were cross-linked to a variety of well-established databases (such as TTD, PubChem and Drug-Bank). All data in the M6AREG database can be viewed, accessed and downloaded online without a login requirement by all users.

CONCLUSION

Epigenetic modifications (e.g. histone modifications, DNA methylation and RNA modifications) regulate gene expression without changing the DNA sequence and play pivotal roles in diseases and drug responses (106–108). RNA methylations are considered as a significant epigenetic modification, and those widely studied include N⁶-methyladenosine (m⁶A), 2'-O-methyladenosine (m⁶Am), N¹-methyladenosine (m¹A), 5-methylcytosine (m⁵C) and pseudouridine (ψ), whose dynamic changes can affect the fate of target RNAs and play critical roles in various bioprocesses. Similar to m⁶A modification, most of these methylation types are modulated by three types of regulators (writer, eraser and reader), and play an important role in affecting the stability, translation, alternative splicing, nuclear export and secondary structure of RNAs. Moreover, different methylation types show diversity in preferred target RNAs and modification sites (109–111). Since the methylations account for >50% of 170 different types of naturally occurring modifications in RNAs (110), it is necessary to develop a system-wide method/tool to facilitate their efficient detection, as well as to explore the molecular mechanism of RNA methylation in target RNAs and their corresponding roles in disease development and drug response.

All in all, the M6AREG is unique in (i) providing the data of m⁶A-centered regulation on disease development and drug responses, (ii) explicitly describing the molecular mechanisms underlying each regulation and (iii) fully referencing the collected data by cross-linking to existing databases. Since the accumulated data in the M6AREG are valuable for researchers in diverse disciplines such as pathology and pathophysiology, clinical laboratory diagnostics, and medicinal biochemistry and drug design, this new

database is expected to have great implications for the future conduct of m⁶A-based regulation studies. M6AREG is now freely accessible and fully downloadable by all users without any login requirement at: <https://idrblab.org/m6areg/>

FUNDING

Funded by the Natural Science Foundation of Zhejiang Province [LQ17H160009 and LR21H300001]; National Natural Science Foundation of China [81802371 and 81872798]; Leading Talent of ‘Ten Thousand Plan’ of the National High-Level Talents Special Support Plan of China; Fundamental Research Fund of Central University [2018QNA7023]; Key R&D Program of Zhejiang Province [2020C03010]; Chinese ‘Double Top-Class’ Universities [181201*194232101]; Start-up Grant of HZNU [4125C5021720421]; China Scholarship Council [201908330151]; Westlake Laboratory (Westlake Laboratory of Life Science and Biomedicine); Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare; Alibaba Cloud; and Information Tech Center of Zhejiang University.

Conflict of interest statement. None declared.

REFERENCES

- Mendel, M., Delaney, K., Pandey, R.R., Chen, K.M., Wenda, J.M., Vagbo, C.B., Steiner, F.A., Homolka, D. and Pillai, R.S. (2021) Splice site m⁶A methylation prevents binding of U2AF35 to inhibit RNA splicing. *Cell*, **184**, 3125–3142.
- Viegas, I.J., de Macedo, J.P., Serra, L., De Niz, M., Temporao, A., Silva Pereira, S., Mirza, A.H., Bergstrom, E., Rodrigues, J.A., Aresta-Branco, F. *et al.* (2022) N⁶-methyladenosine in poly(A) tails stabilize VSG transcripts. *Nature*, **604**, 362–370.
- Wei, J., Yu, X., Yang, L., Liu, X., Gao, B., Huang, B., Dou, X., Liu, J., Zou, Z., Cui, X.L. *et al.* (2022) FTO mediates LINE1 m⁶A demethylation and chromatin regulation in mESCs and mouse development. *Science*, **376**, 968–973.
- Loh, X.Y., Sun, Q.Y., Ding, L.W., Mayakonda, A., Venkatachalam, N., Yeo, M.S., Silva, T.C., Xiao, J.F., Doan, N.B., Said, J.W. *et al.* (2020) RNA-binding protein ZFP36L1 suppresses hypoxia and cell-cycle signaling. *Cancer Res.*, **80**, 219–233.
- Zhu, X., Qiu, C., Wang, Y., Jiang, Y., Chen, Y., Fan, L., Ren, R., Wang, Y., Chen, Y., Feng, Y. *et al.* (2022) FGFR1 SUMOylation coordinates endothelial angiogenic signaling in angiogenesis. *Proc. Natl Acad. Sci. USA*, **119**, e2202631119.
- Wang, A., Zhang, D., Li, Y., Zhang, Z. and Li, G. (2020) Large-scale biomolecular conformational transitions explored by a combined elastic network model and enhanced sampling molecular dynamics. *J. Phys. Chem. Lett.*, **11**, 325–332.
- Wu, S., Zhang, S., Wu, X. and Zhou, X. (2020) m⁶A RNA methylation in cardiovascular diseases. *Mol. Ther.*, **28**, 2111–2119.
- Bayoumi, M. and Munir, M. (2021) Evolutionary conservation of the DRACH signatures of potential N6-methyladenosine (m⁶A) sites among influenza A viruses. *Sci. Rep.*, **11**, 4548.
- Lu, T.X., Zheng, Z., Zhang, L., Sun, H.L., Bissonnette, M., Huang, H. and He, C. (2020) A new model of spontaneous colitis in mice induced by deletion of an RNA m⁶A methyltransferase component METTL14 in T cells. *Cell. Mol. Gastroenterol. Hepatol.*, **10**, 747–761.
- Shen, M., Guo, M., Li, Y., Wang, Y., Qiu, Y., Shao, J., Zhang, F., Xu, X., Yin, G., Wang, S. *et al.* (2022) m⁶A methylation is required for dihydroartemisinin to alleviate liver fibrosis by inducing ferroptosis in hepatic stellate cells. *Free Radic. Biol. Med.*, **182**, 246–259.
- De Jesus, D.F., Zhang, Z., Kahraman, S., Brown, N.K., Chen, M., Hu, J., Gupta, M.K., He, C. and Kulkarni, R.N. (2019) m⁶A mRNA methylation regulates human beta-cell biology in physiological states and in type 2 diabetes. *Nat Metab.*, **1**, 765–774.

12. Han,D., Liu,J., Chen,C., Dong,L., Liu,Y., Chang,R., Huang,X., Liu,Y., Wang,J., Dougherty,U. *et al.* (2019) Anti-tumour immunity controlled through mRNA m⁶A methylation and YTHDF1 in dendritic cells. *Nature*, **566**, 270–274.
13. Lin,Z., Niu,Y., Wan,A., Chen,D., Liang,H., Chen,X., Sun,L., Zhan,S., Chen,L., Cheng,C. *et al.* (2020) RNA m⁶A methylation regulates sorafenib resistance in liver cancer through FOXO3-mediated autophagy. *EMBO J.*, **39**, e103181.
14. Lan,Q., Liu,P.Y., Bell,J.L., Wang,J.Y., Huttelmaier,S., Zhang,X.D., Zhang,L. and Liu,T. (2021) The emerging roles of RNA m⁶A methylation and demethylation as critical regulators of tumorigenesis, drug sensitivity, and resistance. *Cancer Res.*, **81**, 3431–3440.
15. Huang,H., Weng,H. and Chen,J. (2020) m⁶A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer. *Cancer Cell*, **37**, 270–288.
16. Ding,L.W., Sun,Q.Y., Edwards,J.J., Fernandez,L.T., Ran,X.B., Zhou,S.Q., Scolyer,R.A., Wilmott,J.S., Thompson,J.F., Doan,N. *et al.* (2019) LNK suppresses interferon signaling in melanoma. *Nat. Commun.*, **10**, 2230.
17. Sun,Q.Y., Ding,L.W., Johnson,K., Zhou,S., Tyner,J.W., Yang,H., Doan,N.B., Said,J.W., Xiao,J.F., Loh,X.Y. *et al.* (2019) SOX7 regulates MAPK/ERK–BIM mediated apoptosis in cancer cells. *Oncogene*, **38**, 6196–6210.
18. Zhu,X., Ding,S., Qiu,C., Shi,Y., Song,L., Wang,Y., Wang,Y., Li,J., Wang,Y., Sun,Y. *et al.* (2017) SUMOylation negatively regulates angiogenesis by targeting endothelial NOTCH signaling. *Circ. Res.*, **121**, 636–649.
19. Wang,A., Zhang,Y., Chu,H., Liao,C., Zhang,Z. and Li,G. (2020) Higher accuracy achieved for protein–ligand binding pose prediction by elastic network model-based ensemble docking. *J. Chem. Inf. Model.*, **60**, 2939–2950.
20. Liu,T., Wei,Q., Jin,J., Luo,Q., Liu,Y., Yang,Y., Cheng,C., Li,L., Pi,J., Si,Y. *et al.* (2020) The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. *Nucleic Acids Res.*, **48**, 3816–3831.
21. Chen,H., Yao,J., Bao,R., Dong,Y., Zhang,T., Du,Y., Wang,G., Ni,D., Xun,Z., Niu,X. *et al.* (2021) Cross-talk of four types of RNA modification writers defines tumor microenvironment and pharmacogenomic landscape in colorectal cancer. *Mol. Cancer*, **20**, 29.
22. Zhao,Q., Zhao,Y., Hu,W., Zhang,Y., Wu,X., Lu,J., Li,M., Li,W., Wu,W., Wang,J. *et al.* (2020) m⁶A RNA modification modulates PI3K/Akt/mTOR signal pathway in gastrointestinal cancer. *Theranostics*, **10**, 9528–9543.
23. Zhabierli,I., Tzelepis,K., Pandolfini,L., Shi,J., Millan-Zambrano,G., Robson,S.C., Aspris,D., Migliori,V., Bannister,A.J., Han,N. *et al.* (2017) Promoter-bound METTL3 maintains myeloid leukaemia by m⁶A-dependent translation control. *Nature*, **552**, 126–131.
24. Wang,Q., Chen,C., Ding,Q., Zhao,Y., Wang,Z., Chen,J., Jiang,Z., Zhang,Y., Xu,G., Zhang,J. *et al.* (2020) METTL3-mediated m⁶A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance. *Gut*, **69**, 1193–1205.
25. Zhao,Y., Hu,J., Sun,X., Yang,K., Yang,L., Kong,L., Zhang,B., Li,F., Li,C., Shi,B. *et al.* (2021) Loss of m6A demethylase ALKBH5 promotes post-ischemic angiogenesis via post-transcriptional stabilization of WNT5A. *Clin. Transl. Med.*, **11**, e402.
26. Zhang,S., Amahong,K., Zhang,C., Li,F., Gao,J., Qiu,Y. and Zhu,F. (2021) RNA–RNA interactions between SARS-CoV-2 and host benefit viral development and evolution during COVID-19 infection. *Brief. Bioinform.*, **23**, bbab397.
27. Zeng,C., Huang,W., Li,Y. and Weng,H. (2020) Roles of METTL3 in cancer: mechanisms and therapeutic targeting. *J. Hematol. Oncol.*, **13**, 117.
28. Chen,H., Gao,S., Liu,W., Wong,C.C., Wu,J., Wu,J., Liu,D., Gou,H., Kang,W., Zhai,J. *et al.* (2021) RNA N⁶-methyladenosine methyltransferase METTL3 facilitates colorectal cancer by activating the m⁶A–GLUT1–mTORC1 axis and is a therapeutic target. *Gastroenterology*, **160**, 1284–1300.
29. Song,H., Liu,D., Wang,L., Liu,K., Chen,C., Wang,L., Ren,Y., Ju,B., Zhong,F., Jiang,X. *et al.* (2022) Methyltransferase like 7B is a potential therapeutic target for reversing EGFR-TKIs resistance in lung adenocarcinoma. *Mol. Cancer*, **21**, 43.
30. Li,Y.H., Li,X.X., Hong,J.J., Wang,Y.X., Fu,J.B., Yang,H., Yu,C.Y., Li,F.C., Hu,J., Xue,W.W. *et al.* (2020) Clinical trials, progression-speed differentiating features and swiftness rule of the innovative targets of first-in-class drugs. *Brief. Bioinform.*, **21**, 649–662.
31. Xia,W., Zheng,L., Fang,J., Li,F., Zhou,Y., Zeng,Z., Zhang,B., Li,Z., Li,H. and Zhu,F. (2022) PFmulDL: a novel strategy enabling multi-class and multi-label protein function annotation by integrating diverse deep learning methods. *Comput. Biol. Med.*, **145**, 105465.
32. Ma,L., Lin,Y., Sun,S.W., Xu,J., Yu,T., Chen,W.L., Zhang,L.H., Guo,Y.C., Wang,Y.W., Chen,T. *et al.* (2022) KIAA1429 is a potential prognostic marker in colorectal cancer by promoting the proliferation via downregulating WEE1 expression in an m6A-independent manner. *Oncogene*, **41**, 692–703.
33. Gu,Y., Niu,S., Wang,Y., Duan,L., Pan,Y., Tong,Z., Zhang,X., Yang,Z., Peng,B., Wang,X. *et al.* (2021) DMDRM-mediated regulation of m⁶A-modified CDK4 by m⁶A reader IGF2BP3 drives ccRCC progression. *Cancer Res.*, **81**, 923–934.
34. Li,J., Liang,L., Yang,Y., Li,X. and Ma,Y. (2021) N⁶-methyladenosine as a biological and clinical determinant in colorectal cancer: progression and future direction. *Theranostics*, **11**, 2581–2593.
35. Wang,X., Li,F., Qiu,W., Xu,B., Li,Y., Lian,X., Yu,H., Zhang,Z., Wang,J., Li,Z. *et al.* (2022) SYNBP1: synthetic binding proteins for research, diagnosis and therapy. *Nucleic Acids Res.*, **50**, D560–D570.
36. Li,F., Yin,J., Lu,M., Yang,Q., Zeng,Z., Zhang,B., Li,Z., Qiu,Y., Dai,H., Chen,Y. *et al.* (2022) ConSIG: consistent discovery of molecular signature from OMIC data. *Brief. Bioinform.*, **23**, bbac253.
37. Li,F., Zhou,Y., Zhang,Y., Yin,J., Qiu,Y., Gao,J. and Zhu,F. (2022) POSREG: proteomic signature discovered by simultaneously optimizing its reproducibility and generalizability. *Brief. Bioinform.*, **23**, bbac040.
38. Deng,L.J., Deng,W.Q., Fan,S.R., Chen,M.F., Qi,M., Lyu,W.Y., Qi,Q., Tiwari,A.K., Chen,J.X., Zhang,D.M. *et al.* (2022) m6A modification: recent advances, anticancer targeted drug discovery and beyond. *Mol. Cancer*, **21**, 52.
39. Huang,C.S., Zhu,Y.Q., Xu,Q.C., Chen,S., Huang,Y., Zhao,G., Ni,X., Liu,B., Zhao,W. and Yin,X.Y. (2022) YTHDF2 promotes intrahepatic cholangiocarcinoma progression and desensitises cisplatin treatment by increasing CDKN1B mRNA degradation. *Clin. Transl. Med.*, **12**, e848.
40. Li,X., Ma,S., Deng,Y., Yi,P. and Yu,J. (2022) Targeting the RNA m⁶A modification for cancer immunotherapy. *Mol. Cancer*, **21**, 76.
41. Zhao,T., Hu,Y. and Cheng,L. (2021) Deep-DRM: a computational method for identifying disease-related metabolites based on graph deep learning approaches. *Brief. Bioinform.*, **22**, bbaa212.
42. Xue,W., Fu,T., Deng,S., Yang,F., Yang,J. and Zhu,F. (2022) Molecular mechanism for the allosteric inhibition of the human serotonin transporter by antidepressant escitalopram. *ACS Chem. Neurosci.*, **13**, 340–351.
43. Chen,K., Song,B., Tang,Y., Wei,Z., Xu,Q., Su,J., de Magalhaes,J.P., Rigden,D.J. and Meng,J. (2021) RMDisease: a database of genetic variants that affect RNA modifications, with implications for epitranscriptome pathogenesis. *Nucleic Acids Res.*, **49**, D1396–D1404.
44. Xuan,J.J., Sun,W.J., Lin,P.H., Zhou,K.R., Liu,S., Zheng,L.L., Qu,L.H. and Yang,J.H. (2018) RMBase v2.0: deciphering the map of RNA modifications from epitranscriptome sequencing data. *Nucleic Acids Res.*, **46**, D327–D334.
45. Luo,X., Li,H., Liang,J., Zhao,Q., Xie,Y., Ren,J. and Zuo,Z. (2021) RMVar: an updated database of functional variants involved in RNA modifications. *Nucleic Acids Res.*, **49**, D1405–D1412.
46. Tang,Y., Chen,K., Song,B., Ma,J., Wu,X., Xu,Q., Wei,Z., Su,J., Liu,G., Rong,R. *et al.* (2021) m6A-Atlas: a comprehensive knowledgebase for unraveling the N⁶-methyladenosine (m6A) epitranscriptome. *Nucleic Acids Res.*, **49**, D134–D143.
47. Chen,K., Wei,Z., Zhang,Q., Wu,X., Rong,R., Lu,Z., Su,J., de Magalhaes,J.P., Rigden,D.J. and Meng,J. (2019) WHISTLE: a high-accuracy map of the human N⁶-methyladenosine (m6A) epitranscriptome predicted using a machine learning approach. *Nucleic Acids Res.*, **47**, e41.

48. Zheng, Y., Nie, P., Peng, D., He, Z., Liu, M., Xie, Y., Miao, Y., Zuo, Z. and Ren, J. (2018) m6AVar: a database of functional variants involved in m6A modification. *Nucleic Acids Res.*, **46**, D139–D145.
49. Zhou, Y., Zeng, P., Li, Y.H., Zhang, Z. and Cui, Q. (2016) SRAMP: prediction of mammalian N6-methyladenosine (m6A) sites based on sequence-derived features. *Nucleic Acids Res.*, **44**, e91.
50. Liu, H., Wang, H., Wei, Z., Zhang, S., Hua, G., Zhang, S.W., Zhang, L., Gao, S.J., Meng, J., Chen, X. *et al.* (2018) MeT-DB V2.0: elucidating context-specific functions of N6-methyl-adenosine methyltranscriptome. *Nucleic Acids Res.*, **46**, D281–D287.
51. Deng, S., Zhang, H., Zhu, K., Li, X., Ye, Y., Li, R., Liu, X., Lin, D., Zuo, Z. and Zheng, J. (2021) M6A2Target: a comprehensive database for targets of m6A writers, erasers and readers. *Brief. Bioinform.*, **22**, bbaa055.
52. Cheng, L., Qi, C., Yang, H., Lu, M., Cai, Y., Fu, T., Ren, J., Jin, Q. and Zhang, X. (2022) gutMGene: a comprehensive database for target genes of gut microbes and microbial metabolites. *Nucleic Acids Res.*, **50**, D795–D800.
53. Su, R., Dong, L., Li, C., Nachtergaele, S., Wunderlich, M., Qing, Y., Deng, X., Wang, Y., Weng, X., Hu, C. *et al.* (2018) R-2HG exhibits anti-tumor activity by targeting FTO/m6A/MYC/CEBPA signaling. *Cell*, **172**, 90–105.
54. Qing, Y., Dong, L., Gao, L., Li, C., Li, Y., Han, L., Prince, E., Tan, B., Deng, X., Wetzel, C. *et al.* (2021) R-2-hydroxyglutarate attenuates aerobic glycolysis in leukemia by targeting the FTO/m6A/PFKP/LDHB axis. *Mol. Cell*, **81**, 922–939.
55. Dixit, D., Prager, B.C., Gimple, R.C., Poh, H.X., Wang, Y., Wu, Q., Qiu, Z., Kidwell, R.L., Kim, L.J.Y., Xie, Q. *et al.* (2021) The RNA m6A reader YTHDF2 maintains oncogene expression and is a targetable dependency in glioblastoma stem cells. *Cancer Discov.*, **11**, 480–499.
56. Lancet, T. (2018) ICD-11: a brave attempt at classifying a new world. *Lancet*, **391**, 2476.
57. Wishart, D.S., Feunang, Y.D., Guo, A.C., Lo, E.J., Marcu, A., Grant, J.R., Sajed, T., Johnson, D., Li, C., Sayeeda, Z. *et al.* (2018) DrugBank 5.0: a major update to the drugbank database for 2018. *Nucleic Acids Res.*, **46**, D1074–D1082.
58. Zhou, Y., Zhang, Y., Lian, X., Li, F., Wang, C., Zhu, F., Qiu, Y. and Chen, Y. (2022) Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents. *Nucleic Acids Res.*, **50**, D1398–D1407.
59. Sayers, E.W., Beck, J., Bolton, E.E., Bourexis, D., Brister, J.R., Canese, K., Comeau, D.C., Funk, K., Kim, S., Klimke, W. *et al.* (2021) Database resources of the National Center for Biotechnology Information. *Nucleic Acids Res.*, **49**, D10–D17.
60. UniProt, C. (2021) UniProt: the universal protein knowledgebase in 2021. *Nucleic Acids Res.*, **49**, D480–D489.
61. Bruford, E.A., Lush, M.J., Wright, M.W., Sneddon, T.P., Povey, S. and Birney, E. (2008) The HGNC database in 2008: a resource for the human genome. *Nucleic Acids Res.*, **36**, D445–D448.
62. Roundtree, I.A., Evans, M.E., Pan, T. and He, C. (2017) Dynamic RNA modifications in gene expression regulation. *Cell*, **169**, 1187–1200.
63. Li, Y., Su, R., Deng, X., Chen, Y. and Chen, J. (2022) FTO in cancer: functions, molecular mechanisms, and therapeutic implications. *Trends Cancer*, **8**, 598–614.
64. Liu, S., Zhuo, L., Wang, J., Zhang, Q., Li, Q., Li, G., Yan, L., Jin, T., Pan, T., Sui, X. *et al.* (2020) METTL3 plays multiple functions in biological processes. *Am. J. Cancer Res.*, **10**, 1631–1646.
65. Yang, Y., Shen, F., Huang, W., Qin, S., Huang, J.T., Sergi, C., Yuan, B.F. and Liu, S.M. (2019) Glucose is involved in the dynamic regulation of m6A in patients with type 2 diabetes. *J. Clin. Endocrinol. Metab.*, **104**, 665–673.
66. Jiang, H., Cao, K., Fan, C., Cui, X., Ma, Y. and Liu, J. (2021) Transcriptome-wide high-throughput m6A sequencing of differential m6A methylation patterns in the human rheumatoid arthritis fibroblast-like synoviocytes cell line MH7A. *J. Inflamm. Res.*, **14**, 575–586.
67. Liu, S., Li, Q., Chen, K., Zhang, Q., Li, G., Zhuo, L., Zhai, B., Sui, X., Hu, X. and Xie, T. (2020) The emerging molecular mechanism of m6A modulators in tumorigenesis and cancer progression. *Biomed. Pharmacother.*, **127**, 110098.
68. Zhang, S., Amahong, K., Sun, X., Lian, X., Liu, J., Sun, H., Lou, Y., Zhu, F. and Qiu, Y. (2021) The miRNA: a small but powerful RNA for COVID-19. *Brief. Bioinform.*, **22**, 1137–1149.
69. Chien, C.S., Li, J.Y., Chien, Y., Wang, M.L., Yarmishyn, A.A., Tsai, P.H., Juan, C.C., Nguyen, P., Cheng, H.M., Huo, T.I. *et al.* (2021) METTL3-dependent N6-methyladenosine RNA modification mediates the atherogenic inflammatory cascades in vascular endothelium. *Proc. Natl Acad. Sci. USA*, **118**, e2025070118.
70. Zou, Y., Zheng, S., Xie, X., Ye, F., Hu, X., Tian, Z., Yan, S., Yang, L., Kong, Y., Tang, Y. *et al.* (2022) N6-methyladenosine regulated FGFR4 attenuates ferroptotic cell death in recalcitrant HER2-positive breast cancer. *Nat. Commun.*, **13**, 2672.
71. Sun, Y., Gao, X., Wu, P., Wink, M., Li, J., Dian, L. and Liang, Z. (2019) Jatrochicine inhibits mammary carcinoma cells by targeting TNIK mediated Wnt/beta-catenin signalling and epithelial–mesenchymal transition (EMT). *Phytomedicine*, **63**, 153015.
72. Li, Z., Weng, H., Su, R., Weng, X., Zuo, Z., Li, C., Huang, H., Nachtergaele, S., Dong, L., Hu, C. *et al.* (2017) FTO Plays an Oncogenic Role in Acute Myeloid Leukemia as a N6-Methyladenosine RNA Demethylase. *Cancer Cell*, **31**, 127–141.
73. Liu, S., Li, G., Li, Q., Zhang, Q., Zhuo, L., Chen, X., Zhai, B., Sui, X., Chen, K. and Xie, T. (2020) The roles and mechanisms of YTH domain-containing proteins in cancer development and progression. *Am. J. Cancer Res.*, **10**, 1068–1084.
74. Li, B., Jiang, J., Assaraf, Y.G., Xiao, H., Chen, Z.S. and Huang, C. (2020) Surmounting cancer drug resistance: new insights from the perspective of N6-methyladenosine RNA modification. *Drug Resist. Updat.*, **53**, 100720.
75. Feng, M., Xie, X., Han, G., Zhang, T., Li, Y., Li, Y., Yin, R., Wang, Q., Zhang, T., Wang, P. *et al.* (2021) YBX1 is required for maintaining myeloid leukemia cell survival by regulating BCL2 stability in an m6A-dependent manner. *Blood*, **138**, 71–85.
76. Yang, S., Wei, J., Cui, Y.H., Park, G., Shah, P., Deng, Y., Aplin, A.E., Lu, Z., Hwang, S., He, C. *et al.* (2019) m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade. *Nat. Commun.*, **10**, 2782.
77. Jiang, F., Tang, X., Tang, C., Hua, Z., Ke, M., Wang, C., Zhao, J., Gao, S., Jurczynski, A., Janz, S. *et al.* (2021) HNRNPA2B1 promotes multiple myeloma progression by increasing AKT3 expression via m6A-dependent stabilization of ILF3 mRNA. *J. Hematol. Oncol.*, **14**, 54.
78. Lin, X., Chai, G., Wu, Y., Li, J., Chen, F., Liu, J., Luo, G., Tauler, J., Du, J., Lin, S. *et al.* (2019) RNA m6A methylation regulates the epithelial mesenchymal transition of cancer cells and translation of Snail. *Nat. Commun.*, **10**, 2065.
79. Barrett, T., Wilhite, S.E., Ledoux, P., Evangelista, C., Kim, I.F., Tomashevsky, M., Marshall, K.A., Phillippy, K.H., Sherman, P.M., Holko, M. *et al.* (2013) NCBI GEO: archive for functional genomics data sets—update. *Nucleic Acids Res.*, **41**, D991–D995.
80. Fu, J., Zhang, Y., Wang, Y., Zhang, H., Liu, J., Tang, J., Yang, Q., Sun, H., Qiu, W., Ma, Y. *et al.* (2022) Optimization of metabolomic data processing using NOREVA. *Nat. Protoc.*, **17**, 129–151.
81. Tang, J., Fu, J., Wang, Y., Li, B., Li, Y., Yang, Q., Cui, X., Hong, J., Li, X., Chen, Y. *et al.* (2020) ANPELA: analysis and performance assessment of the label-free quantification workflow for metaproteomic studies. *Brief. Bioinform.*, **21**, 621–636.
82. Love, M.I., Huber, W. and Anders, S. (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.*, **15**, 550.
83. Begik, O., Lucas, M.C., Liu, H., Ramirez, J.M., Mattick, J.S. and Novoa, E.M. (2020) Integrative analyses of the RNA modification machinery reveal tissue- and cancer-specific signatures. *Genome Biol.*, **21**, 97.
84. Ritchie, M.E., Phipson, B., Wu, D., Hu, Y., Law, C.W., Shi, W. and Smyth, G.K. (2015) limma powers differential expression analyses for RNA-sequencing and microarray studies. *Nucleic Acids Res.*, **43**, e47.
85. Zhao, Y., Li, M.C., Konate, M.M., Chen, L., Das, B., Karlovich, C., Williams, P.M., Evrard, Y.A., Doroshow, J.H. and McShane, L.M. (2021) TPM, FPKM, or normalized counts? A comparative study of quantification measures for the analysis of RNA-seq data from the NCI patient-derived models repository. *J. Transl. Med.*, **19**, 269.
86. Yang, Q., Li, B., Tang, J., Cui, X., Wang, Y., Li, X., Hu, J., Chen, Y., Xue, W., Lou, Y. *et al.* (2020) Consistent gene signature of

- schizophrenia identified by a novel feature selection strategy from comprehensive sets of transcriptomic data. *Brief. Bioinform.*, **21**, 1058–1068.
87. Yang, Q., Wang, Y., Zhang, Y., Li, F., Xia, W., Zhou, Y., Qiu, Y., Li, H. and Zhu, F. (2020) NOREVA: enhanced normalization and evaluation of time-course and multi-class metabolomic data. *Nucleic Acids Res.*, **48**, W436–W448.
 88. Kumari, R., Ranjan, P., Suleiman, Z.G., Goswami, S.K., Li, J., Prasad, R. and Verma, S.K. (2022) mRNA modifications in cardiovascular biology and disease: with a focus on m6A modification. *Cardiovasc. Res.*, **118**, 1680–1692.
 89. Shi, Y., Fan, S., Wu, M., Zuo, Z., Li, X., Jiang, L., Shen, Q., Xu, P., Zeng, L., Zhou, Y. *et al.* (2019) YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression. *Nat. Commun.*, **10**, 4892.
 90. Du, A., Li, S., Zhou, Y., Disoma, C., Liao, Y., Zhang, Y., Chen, Z., Yang, Q., Liu, P., Liu, S. *et al.* (2022) M6A-mediated upregulation of circMDK promotes tumorigenesis and acts as a nanotherapeutic target in hepatocellular carcinoma. *Mol. Cancer*, **21**, 109.
 91. Yang, Z., Cai, Z., Yang, C., Luo, Z. and Bao, X. (2022) ALKBH5 regulates STAT3 activity to affect the proliferation and tumorigenicity of osteosarcoma via an m6A-YTHDF2-dependent manner. *EBioMedicine*, **80**, 104019.
 92. Kanehisa, M., Furumichi, M., Sato, Y., Ishiguro-Watanabe, M. and Tanabe, M. (2021) KEGG: integrating viruses and cellular organisms. *Nucleic Acids Res.*, **49**, D545–D551.
 93. Bairoch, A. (2018) The cellosaurus, a cell-line knowledge resource. *J. Biomol. Tech.*, **29**, 25–38.
 94. Zhang, Z., Zhang, C., Yang, Z., Zhang, G., Wu, P., Luo, Y., Zeng, Q., Wang, L., Xue, Q., Zhang, Y. *et al.* (2021) m⁶A regulators as predictive biomarkers for chemotherapy benefit and potential therapeutic targets for overcoming chemotherapy resistance in small-cell lung cancer. *J. Hematol. Oncol.*, **14**, 190.
 95. Liu, S., Li, Q., Li, G., Zhang, Q., Zhuo, L., Han, X., Zhang, M., Chen, X., Pan, T., Yan, L. *et al.* (2020) The mechanism of m⁶A methyltransferase METTL3-mediated autophagy in reversing gefitinib resistance in NSCLC cells by beta-elemene. *Cell Death Dis.*, **11**, 969.
 96. Yin, J., Sun, W., Li, F., Hong, J., Li, X., Zhou, Y., Lu, Y., Liu, M., Zhang, X., Chen, N. *et al.* (2020) VARIDT 1.0: variability of drug transporter database. *Nucleic Acids Res.*, **48**, D1042–D1050.
 97. Yin, J., Li, F., Zhou, Y., Mou, M., Lu, Y., Chen, K., Xue, J., Luo, Y., Fu, J., He, X. *et al.* (2021) INTEDE: interactome of drug-metabolizing enzymes. *Nucleic Acids Res.*, **49**, D1233–D1243.
 98. Zhu, F., Shi, Z., Qin, C., Tao, L., Liu, X., Xu, F., Zhang, L., Song, Y., Liu, X., Zhang, J. *et al.* (2012) Therapeutic target database update 2012: a resource for facilitating target-oriented drug discovery. *Nucleic Acids Res.*, **40**, D1128–D1136.
 99. Liu, K., Ouyang, Q.Y., Zhan, Y., Yin, H., Liu, B.X., Tan, L.M., Liu, R., Wu, W. and Yin, J.Y. (2022) Pharmacopitrancriptomic landscape revealing m6A modification could be a drug-effect biomarker for cancer treatment. *Mol. Ther. Nucleic Acids*, **28**, 464–476.
 100. Zhang, S., Sun, X., Mou, M., Amahong, K., Sun, H., Zhang, W., Shi, S., Li, Z., Gao, J. and Zhu, F. (2022) REGLIV: molecular regulation data of diverse living systems facilitating current multiomics research. *Comput. Biol. Med.*, **148**, 105825.
 101. Chen, Z., Shi, T., Zhang, L., Zhu, P., Deng, M., Huang, C., Hu, T., Jiang, L. and Li, J. (2016) Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: a review of the past decade. *Cancer Lett.*, **370**, 153–164.
 102. Bivona, T.G. and Doebele, R.C. (2016) A framework for understanding and targeting residual disease in oncogene-driven solid cancers. *Nat. Med.*, **22**, 472–478.
 103. Hong, J., Luo, Y., Zhang, Y., Ying, J., Xue, W., Xie, T., Tao, L. and Zhu, F. (2020) Protein functional annotation of simultaneously improved stability, accuracy and false discovery rate achieved by a sequence-based deep learning. *Brief. Bioinform.*, **21**, 1437–1447.
 104. Yang, Q., Li, B., Chen, S., Tang, J., Li, Y., Li, Y., Zhang, S., Shi, C., Zhang, Y., Mou, M. *et al.* (2021) MMEASE: online meta-analysis of metabolomic data by enhanced metabolite annotation, marker selection and enrichment analysis. *J. Proteomics*, **232**, 104023.
 105. Fu, T., Li, F., Zhang, Y., Yin, J., Qiu, W., Li, X., Liu, X., Xin, W., Wang, C., Yu, L. *et al.* (2022) VARIDT 2.0: structural variability of drug transporter. *Nucleic Acids Res.*, **50**, D1417–D1431.
 106. Rizzacasa, B., Amati, F., Romeo, F., Novelli, G. and Mehta, J.L. (2019) Epigenetic modification in coronary atherosclerosis: JACC review topic of the week. *J. Am. Coll. Cardiol.*, **74**, 1352–1365.
 107. Song, Y. and Yang, L. (2017) Transgenerational pancreatic impairment with igf2/h19 epigenetic alteration induced by p,p'-DDE exposure in early life. *Toxicol. Lett.*, **280**, 222–231.
 108. Liu, S., Lin, H., Wang, D., Li, Q., Luo, H., Li, G., Chen, X., Li, Y., Chen, P., Zhai, B. *et al.* (2019) PCDH17 increases the sensitivity of colorectal cancer to 5-fluorouracil treatment by inducing apoptosis and autophagic cell death. *Signal Transduct. Target. Ther.*, **4**, 53.
 109. Nombela, P., Miguel-Lopez, B. and Blanco, S. (2021) The role of m⁶A, m⁵C and psi RNA modifications in cancer: novel therapeutic opportunities. *Mol. Cancer*, **20**, 18.
 110. Jin, H., Huo, C., Zhou, T. and Xie, S. (2022) m¹A RNA modification in gene expression regulation. *Genes*, **13**, 910.
 111. Qu, X., Zhang, Y., Sang, X., Ren, D., Zhao, H. and Wong, S.T.C. (2022) Methyladenosine modification in RNAs: from regulatory roles to therapeutic implications in cancer. *Cancers*, **14**, 3195.